Pharma BD Deal Intelligence

Cubist Pharmaceuticals Inc. / Trius Therapeutics Inc.

2013 · Acquisition/Merger · $707M · Complete

Announcement Sentiment

Strongly positive

Cubist to acquire Trius at $13.50/share cash (~$707M fully diluted); added late-stage tedizolid antibiotic plus preclinical antibiotic programs to anti-infective portfolio.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jul 30, 2013
Closed Sep 11, 2013
Deal value $707M
Deal type Acquisition/Merger
Therapeutic area Acute bacterial skin and skin structure infections (ABSSSI)
Indications Acute bacterial skin and skin structure infections (ABSSSI)
Key assets Tedizolid phosphate (TR-701; later Sivextro)
Mechanism Oxazolidinone-class antibiotic (50S ribosomal subunit)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals